Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutic Agents
Biodegradable microbead or microparticle useful for the sustained localized delivery of biologically active proteins or other molecules of pharmaceutical interest
Full description
The described technology is a biodegradable microbead or
microparticle, useful for the sustained localized delivery of
biologically active proteins or other molecules of pharmaceutical
interest. The microbeads are produced from several USP grade
materials, a cationic polymer, an anionic polymer and a binding
component (e.g., gelatin, chondroitin sulfate and avidin), in
predetermined ratios. Biologically active proteins are
incorporated into preformed microbeads via an introduced
binding moiety under nondenaturing conditions.
Proteins or other biologically active molecules are easily
denatured, and once introduced into the body, rapidly cleared.
These problems are circumvented by first incorporating the
protein into the microbead. Microbeads with protein payloads
are then introduced into the tissue of interest, where the
microbeads remain while degrading into biologically innocuous
materials while delivering the protein/drug payload for adjustable
periods of time ranging from hours to weeks. This technology is
an improvement of the microbead technology described in U.S.
Patent No. 5,759,582.
Applications:
This technology has two commercial applications. The first is a
pharmaceutical drug delivery application. The bead allows the
incorporated protein or drug to be delivered locally at high
concentration, ensuring that therapeutic levels are reached at the
target site while reducing side effects by keeping systemic
concentration low. The microbead accomplishes this while
protecting the biologically active protein from harsh conditions
traditionally encountered during microbead formation/drug
formulation.
The microbeads are inert, biodegradable, and allow a sustained
release or multiple-release profile of treatment with various active
agents without major side effects. In addition, the bead maintains
functionality under physiological conditions.
Second, the microbeads and microparticles can be used in
various research assays, such as isolation and separation
assays, to bind target proteins from biological samples. A
disadvantage of the conventional methods is that the proteins
become denatured. The denaturation results in incorrect binding
studies or inappropriate binding complexes being formed. The
instant technology corrects this disadvantage by using a bead
created in a more neutral pH environment. It is this same
environment that is used for the binding of the protein of interest
as well.
Patent information
U.S. Provisional Application No. 60/602,651 filed 19 Aug 2004
(HHS Reference No. E-116-2004/0-US-01); PCT Application No.
PCT/US2005/026257 filed 25 Jul 2005, which published as WO
2006/023207 on 02 Mar 2006 (HHS Reference No. E-116-
2004/0-PCT-02)
Inventor: Phillip F. Heller (NIA)
Type of business relationship sought
Licensees sought: Available for non-exclusive or exclusive
licensing.
Related reports
Jul 2011 - 147 pages - $3,835
Mar 2008 - 6 pages - $400
Jun 2009 - 126 pages - $1,040
Aug 2009 - 128 pages - $1,740
Dec 2010 - 42 pages - $500
Nov 2010 - 39 pages - $500
Sep 2011 - 17 pages - $1,895
Jun 2009 - 8 pages - $295
Nov 2010 - 85 pages - $3,500